Last Updated on January 15, 2019 by Sultan Beardsley
If you are following us and do not yet have a trading account we strongly encourage you to take that first, crucial step, and get one. We are constantly screening for undervalued stocks in the biotech sector. ADMP is just out latest pick recommended on August 27th.
ADMP should continue trending upward in anticipation of approval of it’s prefilled epinephrine syringe, SYMJEPI .15 mg. Chances of approval are high in our opinion because their same proprietary product, SYMJEPI .30 mg is already approved. This means they know exactly what the FDA will and will not accept as adequate for consumers regarding safety and efficacy. Additionally, ADMP has two other speciality pharmaceuticals scheduled for NDA filings this year. Those being APC-6000-Naloxone and sublingual tadalafil (Cialis®), which also stand high chances of approval.
To review our original coverage of ADMP and learn more click here.